X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CIPLA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CIPLA DISHMAN PHARMA/
CIPLA
 
P/E (TTM) x 25.1 44.6 56.3% View Chart
P/BV x 3.3 3.8 87.6% View Chart
Dividend Yield % 0.7 0.3 197.7%  

Financials

 DISHMAN PHARMA   CIPLA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CIPLA
Mar-17
DISHMAN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs374622 60.2%   
Low Rs129458 28.1%   
Sales per share (Unadj.) Rs197.8181.9 108.8%  
Earnings per share (Unadj.) Rs21.212.9 164.8%  
Cash flow per share (Unadj.) Rs34.729.3 118.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.4 214.6%  
Book value per share (Unadj.) Rs179.9155.7 115.5%  
Shares outstanding (eoy) m80.69804.51 10.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.33.0 42.8%   
Avg P/E ratio x11.942.0 28.3%  
P/CF ratio (eoy) x7.218.4 39.3%  
Price / Book Value ratio x1.43.5 40.3%  
Dividend payout %9.415.5 60.7%   
Avg Mkt Cap Rs m20,306434,516 4.7%   
No. of employees `0000.823.0 3.6%   
Total wages/salary Rs m5,35526,338 20.3%   
Avg. sales/employee Rs Th19,252.76,349.1 303.2%   
Avg. wages/employee Rs Th6,459.51,143.0 565.1%   
Avg. net profit/employee Rs Th2,064.1449.3 459.3%   
INCOME DATA
Net Sales Rs m15,961146,302 10.9%  
Other income Rs m2652,287 11.6%   
Total revenues Rs m16,226148,589 10.9%   
Gross profit Rs m4,10324,758 16.6%  
Depreciation Rs m1,09113,229 8.2%   
Interest Rs m9441,594 59.3%   
Profit before tax Rs m2,33412,222 19.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-70 -1.6%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,798 34.7%   
Profit after tax Rs m1,71110,354 16.5%  
Gross profit margin %25.716.9 151.9%  
Effective tax rate %26.714.7 181.7%   
Net profit margin %10.77.1 151.5%  
BALANCE SHEET DATA
Current assets Rs m11,01887,370 12.6%   
Current liabilities Rs m9,51733,081 28.8%   
Net working cap to sales %9.437.1 25.3%  
Current ratio x1.22.6 43.8%  
Inventory Days Days11087 127.1%  
Debtors Days Days3562 55.9%  
Net fixed assets Rs m16,304111,567 14.6%   
Share capital Rs m1611,609 10.0%   
"Free" reserves Rs m12,907123,645 10.4%   
Net worth Rs m14,516125,254 11.6%   
Long term debt Rs m4,18936,454 11.5%   
Total assets Rs m29,805209,532 14.2%  
Interest coverage x3.58.7 40.0%   
Debt to equity ratio x0.30.3 99.2%  
Sales to assets ratio x0.50.7 76.7%   
Return on assets %8.95.7 156.2%  
Return on equity %11.88.3 142.6%  
Return on capital %17.58.5 206.2%  
Exports to sales %24.834.2 72.5%   
Imports to sales %3.78.3 44.8%   
Exports (fob) Rs m3,95650,050 7.9%   
Imports (cif) Rs m59612,203 4.9%   
Fx inflow Rs m4,95251,066 9.7%   
Fx outflow Rs m69717,678 3.9%   
Net fx Rs m4,25533,388 12.7%   
CASH FLOW
From Operations Rs m2,78623,824 11.7%  
From Investments Rs m-1,529-13,127 11.6%  
From Financial Activity Rs m-941-13,239 7.1%  
Net Cashflow Rs m316-2,478 -12.8%  

Share Holding

Indian Promoters % 61.4 16.0 383.8%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.7 12.2 30.3%  
FIIs % 12.7 23.7 53.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 22.1 26.2 84.4%  
Shareholders   46,261 161,166 28.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - ELDER PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS